SEATTLE — May 31, 2022 — Seattle Cancer Care Alliance, now Fred Hutchinson Cancer Center, the only National Cancer Institute (NCI)-designated cancer center in Washington, will have more than 20 clinicians presenting at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022 in Chicago.
Presentations cover a broad range of cancer care topics, from prevention to treatment, and will highlight results from trials in prostate, breast, skin and hematologic cancers. Clinical researchers are also participating in discussions that highlight our organization’s leadership in the multidisciplinary approach to care, cancer survivorship and health equity.
“The work our physician-researchers are sharing this year further demonstrate their unyielding commitment to improving oncology care for every patient,” said Nancy Davidson, MD, Executive Vice President, Clinical Affairs Senior Vice President, Clinical Research Division. “We’re all looking forward to joining the clinical oncology community in person this year and contributing to the collective discoveries advancing cancer care and improving outcomes.”
Real-world practice patterns in the diagnosis of recurrent metastatic breast cancer in Washington state
Author: Poorni Manohar, MD
The relationship between chronic health conditions and employment transitions among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Author: Neel S. Bhatt MBBS, MPH
Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.
Author: Ryan Lynch MD
Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.
Author: Ryan Lynch MD
SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).
Author: David Bing Zhen, MD
CD20: Old Target, New Approach for Lymphoma.
Author: Brian G. Till, MD
Dissecting Racial Disparities in Endometrial Cancer.
Author: Kemi Morenikeji Doll, MD
Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer.
Author: Hiba Khan, MD, MPH (Fellow)
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Author: David Bing Zhen, MD (Second author)
Fred Hutch Media Team